Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19

Next Previous
Trial Profile

A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camostat mesilate (Primary)
  • Indications COVID 2019 infections
  • Focus Pharmacokinetics
  • Acronyms COPS-2002

Most Recent Events

  • 09 Jun 2022 The primary endpoint Time until cessation of shedding of SARS-CoV-2 virus was changed to Area Under the Curve (AUC) of Shedding of SARS-CoV-2 Virus, according to ClinicalTrials.gov record.
  • 08 Jun 2021 Status changed from active, no longer recruiting to completed.
  • 29 Apr 2021 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top